

REMARKS/ARGUMENTS

Reconsideration of the Examiner's rejection of the present application is requested respectfully in view of the following remarks.

STATUS OF THE CLAIMS

At the time of the present Office Action, claims 1 - 8, 11 - 14 and 23 - 26 were pending in this patent application. Claims 7 - 8, 11-14 and 26 have been canceled, without prejudice. No claim have been added. Therefore, claims 1 to 6, and 23 to 25 are presented for consideration.

SUMMARY OF OFFICE ACTION

The Examiner has indicated that claims 1-6 stand allowed.

Claim 7-8, 11-14 and 26 stand rejected under 35 U.S.C. §112, first paragraph, for lack of enablement.

Claims 23-25 stand rejected, but were not discussed in the Office Action.

DISCUSSION


Applicant has canceled claims 7-8, 11-14 and 26, without prejudice to presenting these claims in a future continuing application. Therefore, the rejection of these claims under 35 U.S.C. §112, first paragraph, has been rendered moot.

Claims 1-6 are directed to new compounds, and have been indicated as being allowable by the Examiner. Claims 23-25 also are compound claims which are dependent from the allowed claims. The Examiner has not raised any objections in regard to these claims, and therefore, it is believed that they should be allowed with claims 1-6 .

Therefore, it is submitted that all of the claims pending in the present application are now in condition for allowance, and action to that effect is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment resulting from this Amendment to Deposit Account 18-1982.

Respectfully submitted,



Ronald G. Ort, Reg. No. 26,969
Attorney for Applicant

sanofi-aventis U.S. LLC.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2551
Telefax (908) 231-2626